Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin, celecoxib, and melatonin effects on propofol induction dose in knee replacement surgery
IRCT20191104045328N32Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of gabapentin, celecoxib, melatonin and propofol in total knee arthroplasty (TKA), sponsored by Arak University of Medical Sciences. Primary endpoint: Change in induction dose of propofol. Started Feb 2025; status: completed.
02
Drugs
gabapentincelecoxibmelatoninpropofol
03
Conditions
total knee arthroplasty (TKA)
Beyond the preview
Go deeper on IRCT20191104045328N32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191104045328N32.